Latest Articles
Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer
Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.
BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.
"Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows "impressive" clinical activity in the CNS.
Genetic Counseling Recommended for Advanced Prostate Cancer
A new white paper emphasizes the benefits of germline testing.
Cancer Chemotherapeutics in Rheumatoid Arthritis: A Complex Connection
Research is still needed to explore the association between cancer chemotherapeutics and rheumatoid arthritis.
Predicting Response to Immunotherapy in Late-Stage Melanoma
A new model has the potential to identify patients with melanoma who could benefit from treatment with checkpoint inhibitors.
Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
Identifying Gene Variants Involved in Radiotherapy Toxicity Risk: A Q&A With Benjamin Smith, MD
Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.
FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Surgeon Attitudes May Influence Genetic Testing for Patients With Breast Cancer
The likelihood of a patient with breast cancer receiving genetic analysis more than doubled if she went to a surgeon with a high propensity for ordering such tests.
Liquid Biopsy May Predict Response to Therapy in Diffuse Large B-Cell Lymphoma
Circulating tumor DNA levels measured as early as 3 weeks post-therapy may provide clues about long-term outcomes in this lymphoma subtype.
Robotic Partial Nephrectomy Compared With Open, Laparoscopic Partial Nephrectomy
A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.
Exploring the Role of Immunotherapy in Melanoma Brain Metastases
Although checkpoint inhibitors are active against melanoma-linked brain metastases, researchers are interested in exploring combination approaches.
Clues from DNA Repair Mechanisms Could Drive Novel Therapeutic Strategies
Metabolites from the Krebs cycle were found to suppress the DNA-repair pathway required for the preservation of genomic integrity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer
- Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL